Combination therapies for malaria are failing-what next?

The Lancet Infectious Diseases

Volumn 16, Issue 3, 2016, Pages 274-275

  Saunders, David ^a   Lon, Chanthap ^b  

^a US Army Medical Materiel Development Activity   (United States)

^b Armed Forces Research Institute of Medical Sciences   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE PLUS MEFLOQUINE; ARTESUNATE PLUS PYRONARIDINE; ATOVAQUONE PLUS PROGUANIL; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; PIPERAQUINE; ARTEMISININ DERIVATIVE; QUINOLINE DERIVATIVE;

ANTIMALARIAL DRUG RESISTANCE; CAMBODIA; DIRECTLY OBSERVED THERAPY; DRUG SAFETY; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HUMAN; LENGTH OF STAY; MALARIA; NOTE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; MALARIA FALCIPARUM; MALE; PARASITOLOGY; PLASMODIUM FALCIPARUM;

ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; QUINOLINES;

EID: 84959075066     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00525-3     Document Type: Note

References (11)

1. Amaratunga C, Lim P, Suon S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 2016, published online Jan 7. http://dx.doi.org/10.1016/S1473-3099(15)00487-9.
2. Chaorattanakawee S, Saunders D, Sea D, et al. Ex vivo drug susceptibility and Plasmodium falciparum multidrug resistance gene 1 (pfmdr1) profiling of clinical isolates from Cambodia in 2008-2013 suggest emerging piperaquine resistance. Antimicrob Agents Chemother 2015, 59:4631-4643.
3. Saunders D, Vanachayangkul P, Lon C Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med 2014, 371:484-485.
4. Spring MD, Lin JT, Manning JE, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 2015, 15:683-691.
5. Yeung S, Lawford HL, Tabernero P, et al. Quality of antimalarials at the epicenter of antimalarial drug resistance: results from an overt and mystery client survey in Cambodia. Am J Trop Med Hyg 2015, 92(suppl 6):39-50.
6. Rogers WO, Sem R, Tero T, et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malaria J 2009, 8:10.
7. Kingdom of Cambodia. National treatment guidelines for malaria in the Kingdom of Cambodia 2015, World Health Organization, Geneva.
8. Maude RJ, Nguon C, Dondorp AM, White LJ, White NJ The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment. Malaria J 2014, 13:1-8.
9. Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med 2012, 366:1298-1309.
10. Yadav RP, Nishikiori N, Satha P, Eang MT, Lubell Y Cost-effectiveness of a tuberculosis active case finding program targeting household and neighborhood contacts in Cambodia. Am J Trop Med Hyg 2014, 90:866-872.
11. Manning J, Satharath P, Gaywee J, Lopez MN, Lon C, Saunders D Fighting the good fight: the role of militaries in malaria elimination in Southeast Asia. Trends Parasitol 2014, 30:571-581.